This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Abbott Labs Gets No Respect Despite a Healthy Second Quarter

Stocks in this article: ABT MYL JNJ

NEW YORK (TheStreet) --Abbott Laboratories (ABT) is the proverbial diamond in the rough. It's a healthy company that recently sold its overseas generic pharmaceuticals business to Mylan Laboratories (MYL) for $5.3 billion and then pleased investors with its second-quarter earnings report.

Still, the company's stock isn't getting the respect it deserves. Consider some of the numbers from the second-quarter earnings report Wednesday.

Its ongoing diluted earnings per share was 54 cents in the second quarter, representing year-over-year growth of 17.4%, and above the previous guidance range of 50 cents to 52 cents. Abbott raised its full-year 2014 ongoing EPS guidance to $2.19-$2.29 from $2.16- $2.26, reflecting double-digit growth at the mid-point of the range.

If that isn't impressive enough, none of the financial numbers reported reflected the $5.3 billion Mylan deal. This tax-advantaged transaction involves drugs that are mostly sold throughout Europe and other countries, and is expected to positively affectAbbott's 2015 sales and earnings-per-share growth rates as the company focuses its branded generics pharmaceuticals business on emerging markets.

My research indicates this isn't currently reflected in Abbott's share price.

>>Johnson & Johnson Earnings Beat Boosted by Hepatitis Drug

>>4 Big Stocks Everyone Is Talking About

If that's not enough, during the second quarter Abbott announced agreements to acquire Latin American pharmaceutical company CFR Pharmaceuticals and Russian pharmaceutical company Veropharm. CFR Pharmaceuticals will more than double Abbott's branded generics presence in Latin America while Veropharm gives Abbott a larger footprint and manufacturing presence in Russia.

Abbott's second-quarter 2014 worldwide sales of $5.6 billion increased 3% on an operational basis, and the company is on track for sales growth acceleration in the second half of 2014. International sales, which comprise more than 70 % of total sales, increased 4.2% on an operational basis and 2.7% on a reported basis in the second quarter.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs